Search Results

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021,

Bioventus Inc. has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock.

Accuray Incorporated announced its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.

Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it has received a Health Canada license for the neXus® Ultrasonic Surgical System.

Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be participating in two upcoming investor conferences. BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference Dates: F

Bioventus Inc. (Nasdaq: BVS) (“Bioventus”), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.